Correspondence 0001104659-22-119414 from Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc.
Date: Nov. 16, 2022 · CIK: 0001840233 · Accession: 0001104659-22-119414
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268264
Letter
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, MA 02451
November 16, 2022
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook
Re: Xilio Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-268264 Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-268264), so that it may become effective at 4:00 p.m., Eastern time, on November 18, 2022, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
Very truly yours,
Xilio Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, MA 02451
November 16, 2022
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook
Re: Xilio Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-268264
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as
amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No.
333-268264), so that it may become effective at 4:00 p.m., Eastern time, on November 18, 2022, or as soon as practicable thereafter,
or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
Very truly yours,
Xilio Therapeutics, Inc.
By:
/s/ René Russo
Name: René Russo
Title: Chief Executive Officer